Compare ARK Genomic Revolution ETF (ARKG) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Newmont Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Newmont Corporation trades at $93.67 (market cap $101.73B). The key difference: Newmont Corporation pays a 1.09% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Newmont Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | NEM | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $131.95 |
52-Week Low | $23.09 | $57.35 |
Market Cap | — | $101.73B |
Enterprise Value | — | $98.48B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Newmont Corporation (NEM) trades at $95.29, up 0.51% with bearish technical signals but strong fundamentals. The gold miner reported record Q1 2026 earnings of $2.90 EPS, beating estimates by 40%, with revenue growth accelerating to 46% year-over-year. Analyst consensus remains strongly bullish with 75% buy ratings and a $141 price target representing 48% upside. Cash flow generation reached $3.1 billion in Q1, supporting dividend payments and debt reduction.
Despite gold price volatility creating near-term pressure, Newmont's operational excellence and margin expansion support long-term value. The stock trades at attractive valuations (P/E 12.4x) with 34% net margins, though exposure to commodity cycles and recent technical weakness require careful risk management. The upcoming Q2 earnings on July 23 will be critical for confirming the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
